Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 5/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 5/20 | 1.00 |
| ▸ | RELA | Q04206 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 8/20 | 0.76 |
| ▸ | HPGD | P15428 | 7/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.76 |
| ▸ | NPC1 | O15118 | 7/20 | 0.76 |
| ▸ | POLB | P06746 | 6/20 | 0.76 |
| ▸ | GAA | P10253 | 5/20 | 0.76 |
| ▸ | MAPT | P10636 | 5/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.76 |
| ▸ | MITF | O75030 | 1/20 | 0.76 |
| ▸ | RECQL | P46063 | 1/20 | 0.76 |
| ▸ | GFER | P55789 | 1/20 | 0.76 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.76 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.76 |
| ▸ | PKM | P14618 | 5/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9797268 | 0.93 | KDM4E (0.88) | KDM4ESMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL16142074 | 0.92 | KDM4E (0.85) | KDM4ESMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL16139782 | 0.90 | KDM4E (0.81) | KDM4ESMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL121577 | 0.89 | KDM4E (0.81) | KDM4ESMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL11887840 | 0.88 | KDM4E (0.78) | KDM4ESMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL1744060 | 0.87 | SMN1; SMN2 (0.77) | KDM4ESMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL8531346 | 0.86 | KDM4E (1.00) | KDM4ESMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL12596886 | 0.86 | SMN1; SMN2 (0.74) | KDM4ESMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL6840182 | 0.86 | KDM4E (0.74) | KDM4ESMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL17801688 | 0.86 | KDM4E (0.74) | KDM4ESMN1; SMN2NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3694840-B1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-09-24 | — | — | US | disclosed |
| EP-3694840-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | Hoffmann-La Roche AG (CH) | 2020-08-19 | — | — | EP | disclosed |
| WO-2019072785-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-04-18 | — | — | WO | disclosed |
| CN-109180590-A | A method of Benzoheterocyclic compounds are quickly prepared using physical grinding method under room temperature solvent-free | 福建医科大学 | 2019-01-11 | — | — | CN | disclosed |
| EP-2611774-B1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-18 | — | — | EP | disclosed |
| EP-2611774-B1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-18 | — | — | EP | disclosed |
| US-8962607-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-24 | — | — | US | disclosed |
| US-8962607-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-24 | — | — | US | disclosed |
| WO-2010124082-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124086-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124116-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| CN-100434420-C | Compounds that block dipeptidyl peptidase IV | SANWA KAGAKU KENKYUSHO CO (JP) | 2008-11-19 | — | — | CN | disclosed |
| US-7345180-B2 | Compound inhibiting dipeptidyl peptidase IV | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2008-03-18 | — | — | US | disclosed |
| US-20060229286-A1 | Compound inhibiting dipeptidyl peptidase IV | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| CN-1745063-A | Compound inhibiting dipeptidyl peptidase iv | SANWA KAGAKU KENKYUSHO CO (JP) | 2006-03-08 | — | — | CN | disclosed |
| EP-1595866-A1 | COMPOUND INHIBITING DIPEPTIDYL PEPTIDASE IV | Sanwa Kagaku Kenkyusho Co., Ltd. (JP) | 2005-11-16 | — | — | EP | disclosed |
| EP-0119192-A1 | LIQUID CRYSTALLINE POLYMER COMPOSITIONS, PROCESS, AND PRODUCTS | SRI INTERNATIONAL (US) | 1984-09-26 | — | — | EP | disclosed |
| WO-1984001160-A1 | LIQUID CRYSTALLINE POLYMER COMPOSITIONS, PROCESS, AND PRODUCTS | STANFORD RES INST INT (US) | 1984-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | MAGI3, PYM1, MAG | KDM4E 2009/4885SMN1; SMN2 1928/4885NFKB1 3238/4885 |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | MAGI3, PYM1, MAG | KDM4E 2009/4885SMN1; SMN2 1928/4885NFKB1 3238/4885 |
| US-20060229286-A1 | Compound inhibiting dipeptidyl peptidase IV | DPP4, DPP3, DPP7 | KDM4E 2352/4885SMN1; SMN2 2474/4885NFKB1 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.